aiwiki.page
English
Health / Diseases & Symptoms / acute-intermittent-porphyria

Acute intermittent porphyria

Acute intermittent porphyria is an inherited disorder of heme synthesis that can cause episodic abdominal pain, autonomic disturbances, psychiatric symptoms, and potentially severe nerve damage.

19 keywords2 linked from3 not yet writtenWritten by AI
EnzymeHemePorphyriaAbdominal painGeneAutosomal Domina…NauseaConstipationAcute inte…

Acute intermittent porphyria (AIP) is an inherited metabolic disorder caused by reduced activity of hydroxymethylbilane synthase, an enzyme involved in the production of heme. It belongs to the acute hepatic porphyrias, a group of disorders in which excessive production of heme precursors in the liver can cause attacks affecting the nervous system. Its characteristic presentation combines severe abdominal pain with autonomic, neurological, or psychiatric disturbances. Most people who carry an AIP-associated genetic variant never develop an acute attack.

Biochemical and genetic basis

Heme is an iron-containing component of hemoglobin, cytochromes, and numerous other proteins. Its synthesis requires a sequence of eight enzymatic reactions. In AIP, a disease-causing variant in the HMBS gene reduces activity of hydroxymethylbilane synthase, also called porphobilinogen deaminase. This enzyme normally converts porphobilinogen into hydroxymethylbilane, an early intermediate in heme synthesis.

When hepatic heme synthesis is stimulated, this partial enzymatic block can lead to accumulation of two upstream precursors: delta-aminolevulinic acid (ALA) and porphobilinogen (PBG). ALA is considered an important contributor to neurotoxicity, although the mechanisms producing the full clinical syndrome are not completely understood.

AIP usually follows autosomal dominant inheritance. A person with one disease-causing HMBS variant has a 50% probability of transmitting it to each child. However, inheritance of the variant does not mean that symptoms will occur: AIP has low clinical penetrance, and environmental, hormonal, and additional genetic factors influence its expression. Penetrance is higher in families identified through symptomatic patients than among carriers detected in general-population studies.

The enzyme defect is inherited, but the liver is the principal source of the excess precursors responsible for attacks. This distinguishes the site driving symptoms from the tissues injured by the disease.

Clinical manifestations

Acute attacks

An attack typically develops over hours to days and may last several days or longer. Severe, poorly localized abdominal pain is the most common feature. Despite its intensity, the pain may occur without marked abdominal guarding or an explanatory abnormality on imaging. Associated manifestations include:

  • Nausea, vomiting, and constipation, sometimes with intestinal ileus.
  • Rapid heart rate, hypertension, sweating, and urinary retention.
  • Anxiety, agitation, insomnia, confusion, or hallucinations.
  • Muscle pain and weakness caused by motor-predominant peripheral neuropathy.
  • Low blood sodium, or hyponatremia, sometimes associated with seizures.

Neurological involvement can affect the peripheral nervous system, autonomic pathways, and central nervous system. Severe motor neuropathy may progress to paralysis and respiratory muscle weakness requiring mechanical ventilation. Recovery from substantial nerve injury can take months and may be incomplete.

Urine may become reddish-brown, particularly after standing or exposure to light, but this is neither a consistent finding nor a diagnostic test. AIP does not cause the blistering photosensitivity characteristic of some other porphyrias.

Triggers and course

Attacks are uncommon before puberty and occur more often in women than in men during reproductive adulthood. Recognized precipitating factors include certain medicines, fasting or substantial caloric restriction, alcohol, intercurrent illness, and hormonal changes. Some attacks occur without an identifiable trigger. In a subset of affected women, episodes follow a menstrual pattern.

Many symptomatic individuals experience only one or a few attacks, while a smaller group develops recurrent episodes. Some people with recurrent disease also experience persistent pain, fatigue, or neurological symptoms between attacks; “intermittent” therefore does not describe every disease course.

Diagnosis

Biochemical testing

The central investigation during a suspected attack is measurement of urinary PBG, usually together with ALA and urine creatinine in a random urine sample. Expressing concentrations relative to creatinine helps account for urine dilution. Samples require appropriate handling, including protection from light.

PBG and ALA are markedly elevated during an AIP attack. However, elevated PBG also occurs in other acute hepatic porphyrias, and levels can remain high after an attack has resolved. A positive result therefore requires interpretation alongside symptoms and further testing. Conversely, normal PBG and ALA during active symptoms, in a properly collected sample obtained before precursor-lowering treatment, make an acute porphyria attack unlikely.

Measurement of total urinary porphyrins alone is insufficient: nonspecific elevations occur in several other conditions and can lead to misdiagnosis.

Establishing the subtype

After biochemical evidence of acute hepatic porphyria, specialist testing can include plasma and fecal porphyrin profiles and HMBS genetic analysis. Identification of a pathogenic variant supports the specific diagnosis and enables targeted testing of relatives. A genetic finding alone does not establish that current symptoms are caused by an acute attack.

The differential diagnosis includes surgical abdominal conditions, toxic exposures such as lead poisoning, metabolic disturbances, and other causes of neuropathy or encephalopathy. Variegate porphyria and hereditary coproporphyria can produce similar acute attacks but may also cause cutaneous photosensitivity.

Treatment

Established treatment for a significant acute attack centers on intravenous hemin, supplied in different formulations according to jurisdiction. Hemin suppresses hepatic ALA synthase 1, the rate-limiting enzyme of liver heme synthesis, reducing further production of ALA and PBG. It does not immediately reverse established nerve injury.

Clinical management also includes treatment of pain and vomiting, correction of fluid and electrolyte abnormalities, adequate nutrition, and monitoring for neurological or respiratory deterioration. Carbohydrate administration can suppress precursor production to a limited extent but is less potent than hemin. Medication selection requires particular care because some drugs stimulate hepatic heme demand or otherwise precipitate attacks.

For recurrent acute hepatic porphyria, givosiran is an established disease-specific treatment. It uses RNA interference to reduce hepatic ALA synthase 1 production and thereby lower ALA and PBG. Its use involves monitoring for adverse effects, including hepatic and renal abnormalities. Preventive hemin treatment is another approach used in selected patients, although repeated administration can cause complications such as iron overload and problems associated with venous access.

Liver transplantation can eliminate the hepatic source of excess precursors and prevent further attacks. Because of its substantial risks, it is reserved for exceptional cases of severe, otherwise uncontrolled disease.

Long-term complications and family implications

Symptomatic AIP is associated with chronic kidney disease and persistent hypertension. Acute hepatic porphyrias also confer an increased risk of primary liver cancer, particularly later in adulthood; this can occur without established cirrhosis. Specialist follow-up may therefore include assessment of kidney function, blood pressure, and liver cancer surveillance.

Once a familial pathogenic variant is identified, testing can distinguish relatives who carry it from those who do not. Genetic counseling addresses inheritance, the difference between carrier status and symptomatic disease, and the limitations of predicting whether an individual will develop attacks.